Cited by 236Cellular transport and secretionHepatocellular Carcinoma Treatment and PrognosisHER2/EGFR in Cancer Research

GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis

Open access
Ye, Qing-Hai, Zhu, Wen-Wei, Zhang, Ju-Bo, Qin, Yi, Lu, Ming, Lin, Guo-Ling, Guo, Lei, Zhang, Bo +12 more·2016·Cancer Cell

Abstract

The mechanism of cancer metastasis remains poorly understood. Using gene profiling of hepatocellular carcinoma (HCC) tissues, we have identified GOLM1 as a leading gene relating to HCC metastasis. GOLM1 expression is correlated with early recurrence, metastasis, and poor survival of HCC patients. Both gain- and loss-of-function studies determine that GOLM1 acts as a key oncogene by promoting HCC growth and metastasis. It selectively interacts with epidermal growth factor receptor (EGFR) and serves as a specific cargo adaptor to assist EGFR/RTK anchoring on the trans-Golgi network (TGN) and recycling back to the plasma membrane, leading to prolonged activation of the downstream kinases. These findings reveal the functional role of GOLM1, a Golgi-related protein, in EGFR/RTK recycling and metastatic progression of HCC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2016.07.017

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dysregulation of GARGs has been implicated in tumor progression, therapy resistance, and remodeling of the immune microenvironment across multiple cancer types.

    “Dysregulation of GARGs has been implicated in tumor progression, therapy resistance, and remodeling of the immune microenvironment across multiple cancer types.”

    From Construction and validation of golgi apparatus-related genes as predictors of the immune microenvironment and prognosis in colorectal cancer (2026) · cites this paper as [14]

    The Results and Discussion (page numbers unavailable in our copy) identify GOLM1 as an upregulated Golgi-associated gene that promotes hepatocellular carcinoma growth and metastasis. They do not establish that GARGs as a group drive therapy resistance or immune-microenvironment remodeling across multiple cancer types. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 44 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Ye, Q.-H., Zhu, W.-W., Zhang, J.-B., Qin, Y., Lu, M., Lin, G.-L., Guo, L., Zhang, B., Lin, Z.-H., Roessler, S., Forgues, M., Jia, H.-L., Lu, L., Zhang, X.-F., Lian, B.-F., Xie, L., Dong, Q.-Z., Tang, Z.-Y., Wang, X. W., & Qin, L.-X.
Affiliations
  • Fudan University (CN)
  • National Institutes of Health (US)
  • Shanghai Center For Bioinformation Technology (CN)
  • Shanghai Medical College of Fudan University (CN)
Corresponding author
  • Wang, Xin Wei
  • Qin, Lun-Xiu
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2016-09
Volume
30
Issue
3
Pages
444-458
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2514993735
Cited by
228
References
44
Citations by year
2026: 7 · 2025: 12 · 2024: 26 · 2023: 29 · 2022: 24 · 2021: 46 · 2020: 27 · 2019: 25 · 2018: 19 · 2017: 10 · 2016: 2
FWCI
12.86
Type
journal article
Language
en
Open access
Locations
  • Cancer Cell (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • State Key Basic Research Program of China (2013CB910500, 2009CB521701)
  • National Key Project for Infectious Disease of China (2012ZX10002012)
  • National Natural Science Foundation of China (81472677, 81372654, 81071993, 30872505, 30672037, 30300400, 30700991)
  • National Cancer Institute (Z01 BC 010313, Z01 BC 010877)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
GOLM1, hepatocellular carcinoma, metastasis, EGFR, receptor tyrosine kinase, trans-Golgi network, cargo adaptors, oncogenes, tumor recurrence, kinase activation
MeSH terms
Adolescent, Adult, Aged, Animals, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Membrane Proteins, Mice, Inbred BALB C, Mice, Nude, Middle Aged, Neoplasm Metastasis, Transfection, Up-Regulation, Cell Line, Tumor, Mice, Young Adult, Heterografts, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review